Twist Bioscience Corp vs Western Digital Corp — how do they compare? Twist Bioscience Corp trades at $161.93 (market cap $10.08B), while Western Digital Corp trades at $395.65 (market cap $147.23B). The key difference: Western Digital Corp is far larger — about 14.6× Twist Bioscience Corp's market cap, and Western Digital Corp pays a 0.15% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Western Digital Corp for 37 Days on average.
| TWST | WDC | |
|---|---|---|
Market Cap | $10.08B | $147.23B |
Volume | 4,229,037 | 9,341,468 |
Sector | Health | Technology |
52-Week High | $205.00 | $746.23 |
52-Week Low | $25.45 | $113.13 |
Typical Hold Time | 27 Days | 37 Days |
Enterprise Value | $10.01B | $146.70B |
Dividend Yield | — | 0.15% |
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $159.78, up 2.65% today, showing strong momentum despite mixed technical signals. The company continues to demonstrate robust revenue growth, with 2025 revenue reaching $377 million, though profitability remains elusive with a -31.66% net income margin. Recent positive developments include a strategic partnership with Eli Lilly's TuneLab AI platform announced September 16, 2026, driving investor optimism about the company's AI-driven drug discovery capabilities.
While analyst consensus remains bullish with 73% buy ratings, the stock faces significant fundamental challenges including persistent cash burn and negative earnings. The current price exceeds the $145.20 consensus target, suggesting limited near-term upside. Key risks include execution challenges in achieving profitability and dependence on AI partnerships for growth catalysts.
Western Digital (WDC) trades at $397.28, down 1.96% amid recent sector volatility. The stock shows strong fundamentals with a 14.61 P/E ratio and impressive 71.97% net income margin, supported by three consecutive quarterly earnings beats. Technical indicators suggest bearish momentum with the price near pivot point support at $397. Recent news highlights competitive pressures from Toshiba's planned HDD production expansion, contributing to the stock's recent decline.
WDC presents a compelling value opportunity with strong profitability metrics and analyst consensus favoring bullish sentiment (72% buy ratings). However, investors face near-term risks from increased competition in AI storage markets and potential margin pressure. The $647.58 consensus price target suggests significant upside potential if the company maintains its competitive positioning and executes on growth initiatives.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →